Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.

Conclusion: Our results indicate that MELK is ubiquitously overexpressed in iCCA, where it may represent a prognostic indicator and a therapeutic target. In particular, the combination of OTSSP167 (or other, more specific MELK inhibitors) with DNA-damaging agents might be a potentially effective therapy for human iCCA. PMID: 31861475 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31861475?dopt=Abstract

Source: Medicina (Kaunas) - December 17, 2019 Category: Universities & Medical Training Authors: Cigliano A, Pilo MG, Mela M, Ribback S, Dombrowski F, Pes GM, Cossu A, Evert M, Calvisi DF, Utpatel K Tags: Medicina (Kaunas) Source Type: research